A Cautionary Tale: The Unseen Risks of Low-Dose Propofol in Palliative Care
A recent editorial in *Anaesthesia* sounds a critical warning about the use of low-dose propofol infusions for managing refractory symptoms in end-of-life care. While the promise of inducing unconsciousness to relieve terminal suffering is compelling, the article highlights significant, underappreciated risks. These include profound hypotension, unpredictable pharmacokinetics in critically ill patients, and the potential for drug-induced kidney injury due to prolonged exposure and metabolic byproducts. The piece argues for a more cautious, evidence-based approach, emphasizing that the ethical imperative to relieve suffering must be balanced against the very real dangers of causing iatrogenic harm, including acute kidney injury, in a vulnerable population.
Study Significance: For nephrologists managing patients with advanced chronic kidney disease or end-stage renal disease, this warning is directly pertinent to complex palliative care decisions. It underscores the need for heightened vigilance regarding nephrotoxicity and hemodynamic instability when sedatives are used, factors that can precipitate acute kidney injury or complicate existing renal failure. This analysis should inform more nuanced protocols for symptom management in renal palliative care, ensuring that therapeutic intentions do not inadvertently accelerate decline through preventable renal complications.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
